Low birth weight is associated with increased risk for Attention Deficit/Hyperactivity Disorder (ADHD); however, the etiologi cal underpinnings of this relationship remain unclear. This study investigated if genetic variants in angiogenic, dopaminergic, neurotrophic, kynurenine, and cytokine-related biological path ways moderate the relationship between birth weight and ADHD symptom severity. A total of 398 youth from two multi-site, family-based studies of ADHD were included in the analysis. The sample consisted of 360 ADHD probands, 21 affected siblings, and 17 unaffected siblings. A set of 164 SNPs from 31 candidate genes, representing five biological pathways, were included in our analyses. Birth weight and gestational age data were collected from a state birth registry, medical records, and parent report.
INTRODUCTION
Attention-Deficit/Hyperactivity Disorder (ADHD) is character ized by persistent, pervasive, and developmentally inappropriate levels of inattention, hyperactivity-impulsivity, or both. ADHD arises from the complex interplay between genetic and environ mental factors [Thapar et al., 2013] . Consequently, there are likely to be multiple etiological pathways leading from early risk to the development of the disorder [Sonuga-Barke and Halperin, 2010; Thapar et al., 2013] . In particular, environmental insults during prenatal development have the potential to have lasting effects on neurodevelopmental risk for ADHD [Lou, 1996; Toft, 1999; Lou et al., 2004; Mill and Petronis, 2008] . Although multiple prenatal environmental risk factors for ADHD have been identified [Bane rjee et al., 2007; Nigg et al., 2010; Froehlich et al., 2011] , specific developmental mechanisms that contribute to the emergence of ADHD are poorly understood.
Restricted fetal growth phenotypes, like low birth weight (<2,500 g) and small for gestational age, are among the strongest risk factors for ADHD and lead to 1.5 to 3-fold increase in ADHD risk [Breslau et al., 1996; Mick et al., 2002; Indredavik et al., 2004; Linnet et al., 2006; Boulet et al., 2009] . The strength of this association, however, varies across studies [Nigg, 2006] and is not always replicated [Cornforth et al., 2012] . Consistent with the dimensional nature of ADHD [Levy et al., 1997; Coghill and Sonuga-Barke, 2012] , the association between lower birth weight and ADHD-related phenotypes is continuous and extends into the normal birth weight range [Boulet et al., 2009; Phua et al., 2012; Qiu et al., 2012; Walhovd et al., 2012] . Lower birth weight is also associated with reduced anterior cingulate cortex, caudate nucleus, and total brain volumes [Peterson et al., 2003; Tolsa et al., 2004; de Kieviet et al., 2012; Walhovd et al., 2012] , which are linked with ADHD behavioral symptomatology [Frodl and Skokauskas, 2012; Hart et al., 2013] . Identifying biological mechanisms that contribute to the association between lower birth weight and ADHD may further elucidate early develop mental pathways to ADHD.
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Similar to ADHD [Thapar et al., 2013] , birth weight has multifactorial origins and a substantial heritability estimate [MookKanamori et al., 2012] . This allows for the possibility that birth weight and ADHD share a common genetic liability. Twin studies, however, demonstrate that prenatal environmental factors, rather than shared genetic factors, largely account for the relationship between birth weight and ADHD symptoms [Lehn et al., 2007; Groen-Blokhuis et al., 2011; Ficks et al., 2013; Sharp et al., 2003] or externalizing behavior [van Os et al., 2001; Wichers et al., 2002] . This suggests that environmental determinants of lower birth weight contribute to the development of ADHD.
Suboptimal maternal-placental-fetal nutrient and oxygen trans port (e.g., placental insufficiency) is associated with restricted fetal growth in most cases [Ghidini, 1996; Hendrix et al., 2008] . Prenatal ischemia-hypoxia is considered the primary pathway to lower birth weight, especially in well-nourished populations [Henriksen et al., 2002] . Placental insufficiency and fetal growth restriction are associated with altered angiogenic [Conde-Agudelo et al., 2013] , dopaminergic [Vucetic et al., 2010] , neurotrophic [MalamitsiPuchner et al., 2007] , and inflammatory responses [Amarilyo et al., 2011] , and numerous poor neurodevelopmental outcomes [Baschat, 2011] . Prenatal ischemia-hypoxia is a common element to multiple early risk factors for ADHD including maternal smok ing [Bush et al., 2000] and maternal alcohol use during pregnancy [Bosco and Diaz, 2012] as well as ischemia-hypoxia related obstetric complications [Pineda et al., 2007; Rennie et al., 2007; Getahun et al., 2013] . Consistent with the Developmental Origins of Health and Disease (DOHaD) framework [Gluckman et al., 2004; Mill et al., 2008; Swanson and Wadhwa, 2008; Swanson et al., 2009; Wadhwa et al., 2009] , the association between lower birth weight and ADHD may arise from prenatal ischemia-hypoxia. Prenatal ischemia-hypoxia may directly disrupt or delay development or lead to structural or functional adaptations to the adverse intra uterine environment. Such adaptations, however, may leave the individual ill-equipped to function in a nutrient and oxygen rich postnatal environment. For example, in response to prenatal ischemia-hypoxia some fetuses preferentially redistribute blood flow to the brain, known as the "brain-sparing effect" [Roza et al., 2008] . Fetuses that demonstrate "brain-sparing" circulation may be better protected from the immediate adverse effects of ischemia-hypoxia, however, these fetuses may exhibit decreased cerebral vascular plasticity [Fu et al., 2006] and increased behavioral problems [Roza et al., 2008; Figueras et al., 2011] . Genetic variabil ity in key ischemia-hypoxia related developmental systems may further alter susceptibility to ADHD, following an adverse intra uterine environment.
Few studies have investigated how the interplay between fetal growth and genetic variability contributes to ADHD's complex pathophysiology. Langley et al. (2008) found that "classic" candi date neurotransmitter gene (DAT1, DRD4, DRD5, and SLC6A4) variants did not moderate the association between birth weight and ADHD. Another study reported that ADHD youth who also had low birth weight were at increased risk for early-onset antisocial behavior if they possessed the COMT Val/Val genotype [Thapar et al., 2005] . This finding, however, was not replicated in a separate ADHD clinical sample [Sengupta et al., 2006] . To examine mech anisms linking fetal growth with ADHD, it may be important to broaden the search to genes implicated in the response to prenatal ischemia-hypoxia, a main determinant of restricted fetal growth.
Prenatal ischemia-hypoxia impacts multiple neurodevelopmen tal systems [Schmidt-Kastner et al., 2012; Zhang et al., 2012; Wang et al., 2013] . Of the many systems implicated in the ischemia hypoxia response, dopaminergic [Levy, 1991; Swanson et al., 2007] , neurotrophic [Ribases et al., 2008; Sanchez-Mora et al., 2009] , angiogenic [Kim et al., 2002; Jesmin et al., 2004] , kynurenine [Oades, 2011] and cytokine systems [Oades, 2011] are also impli cated in the development of ADHD and related conditions. There fore, genetic variants within these five systems were the focus of this study. Variability in genes regulating these systems may alter vulnerability to the effects of prenatal ischemia-hypoxia leading to the neurodevelopmental deficits that mediate the ADHD behav ioral phenotype [Toft, 1999; Shaw et al., 2006; Rapoport and Gogtay, 2008] . To address this hypothesis, we examined interac tions between genetic variants within ischemia-hypoxia response systems and birth weight centile, adjusted for gestational age, to predict ADHD symptom severity. We predicted that: (i) lower birth weight centile would be associated with increased ADHD symp tomatology; and (ii) SNPs within dopaminergic, neurotrophic, angiogenic, kynurenine and cytokine system genes would moderate the association between birth weight centile and ADHD symptom severity.
MATERIALS AND METHODS Subjects
Participants were drawn from two larger studies -the North Carolina Genetics of ADHD Project [NCGAP; Kollins et al., 2008; Anastopoulos et al., 2011] and the International Multisite ADHD Genetics Project [IMAGE; Brookes et al., 2006; Kuntsi et al., 2006; Neale et al., 2008b] , the latter including 12 enrollment sites within Europe and Israel. The current analysis was conducted on a subset of the NCGAP and IMAGE samples who were singleton births and had birth weight, gestational age, and genome-wide single nucleotide polymorphism (SNP) data. Birth weight and gestational age data were only available for IMAGE study sites in the United Kingdom, Ireland and the Netherlands. Furthermore, we only included Caucasian participants due to genotype imputation procedures (described below). Of the 398 [Neale et al., 2008a] , DSM-IV ADHD diagnoses were based on parental responses to a clinical interview as well as teacher and/or parent responses to behavior rating scales. This study was approved by the affiliated institutional review boards and conducted in accordance with human subjects guidelines.
Measures
Conners' parent rating scale (CPRS; Conners, 1997) . Parent responses to the CPRS 18-item DSM-IV ADHD total subscale, as well as 9-item Inattentive and Hyperactive-Impulsive subscales were summed and converted to t-scores adjusting for age and gender of each participant [Conners et al., 1998 ]. Parents were instructed to rate their child's ADHD symptoms when not taking medication prescribed for ADHD. The resulting scores were con tinuous measures of ADHD symptom severity and served as out comes in this study. The CPRS ADHD Total (skewness ¼ -0.81; SE ¼ 0.12), Inattentive (skewness ¼ -0.50; SE ¼ 0.12), and Hyper active-Impulsive (skewness ¼ -0.85; SE ¼ 0.12) scores were nonnormally distributed. Therefore, transformed CPRS ADHD Total (square root of reflected score transformation; skewness ¼ -0.03; SE ¼ 0.12), Inattentive (squared transformation; skewness ¼ <0.01; SE ¼ 0.12), and Hyperactive-Impulsive scores (square root transformation; skewness ¼ -0.07; SE ¼ 0.12) were selected for analysis based on normality.
Birth weight centile range. Birth weight centiles were calculat ed for each participant adjusting for gestational age and sex, based on separate normative samples for the Netherlands, United Kingdom/Ireland, and United States participants.
NCGAP. Birth weight and gestational age for the NCGAP sample was retrieved through medical records, parental report, and state birth registry. Birth weight centiles for NCGAP were created using all singleton births from 2000xps12004 from the CDC National Vital Statistics natality files. For consistency, indi vidual centiles were then converted to the centile ranges described below.
IMAGE. For the Dutch sample, birth weight and gestational age were obtained through retrospective parent report. The Netherlands Perinatal Registry reference curves were used to cal culate birth weight centiles for the Dutch sample [Visser et al., 2009] . The Netherlands Perinatal Registry reference curves provide 11 normative references at 2. 3, 5, 10, 16, 20, 50, 80, 84, 90, 95, and 97.7 centiles [Visser et al., 2009] . Therefore, 12 birth weight centile ranges were created (0-2. 29, 2.3-4.9, 5-9.9, 10-15.9, 16-19.9, 20-49.9, 50-79.9, 80-83.9, 84-89.9, 90-94.9, 95-97.6, 97.7-100) . Lower scores on the resulting ordinal severity scale of birth weight centile ranges represented higher levels of fetal growth restriction.
Birth weight and gestational age for samples from Ireland and the UK were obtained from retrospective parent report. The UK reference curves [Pan et al., 2010; Cole et al., 2011] were used to calculate birth weight centiles for the UK and Ireland samples, based on birth weight, gestational age, and sex. For consistency, individual birth weight centiles were converted to birth weight centile ranges identical to those created in the Dutch sample.
Genotyping. SNP genotyping for the NCGAP subsample was performed using the Illumina Infinium HumanHap300 duo (Illumina, Inc., San Diego, CA) at the Center for Human Genetics at Duke University Medical School. Two Centre d'Etude du Polymorphism Humain (CEPH) controls and blinded duplicates were used for every 94 samples and required to match 100%. Additional quality checks of the genotyping data were examined using PLINK [Purcell et al., 2007] . Call rates exceeded 98% for all individuals. Individuals were excluded due to gender discrepancy and if per-family Mendelian errors were in excess of 1%. SNPs were excluded from analysis if they had Mendelian errors in >4 families or deviated from Hardy-Weinberg Equilibrium (HWE; P < 0.000001).
SNP genotyping for the IMAGE subsample was performed at Perlegen Sciences (Mountain View, CA) on a microarray designed for the Genetic Association Information Network (GAIN). Quality checks were completed by the National Center for Biotechnology Information (NCBI) using GAIN QA/QC, version 0.7.4 [Abecasis Gopalakirshnana] . Individuals were excluded due to gender dis crepancy and if per-family Mendelian errors were in excess of 2%. SNPs were excluded if the: (i) call rate was <95%; (ii) heterozygosity was >32%; (iii) discrepancy in SNP call was <10% in whole sample; or (iv) HWE P < 0.000001.
Candidate genes were selected based of literature review of candidate signaling pathways [Reichardt, 2006; Shibuya, 2008] , ischemia-hypoxia response genes [Schmidt-Kastner et al., 2006] , ADHD etiological studies [Gizer et al., 2009; Oades et al., 2010; Oades, 2011] and genotyping platform coverage. SNPs within dopaminergic (COMT, DAT1, DRD2, DRD3, and DRD5), neuro trophic (BDNF, NGF, NT3, NGFR, NTRK1, NTRK2, and NTRK3), angiogenic (VEGFA, VEGFR1, VEGFR2, NRP1, NRP2, HIF1A, and HIF1AN), kynurenine (CCBL1, CCBL2, and KYNU) and cytokine related genes (CNTF, CNTFR, CRLF1, IL6, IL13, IL16, LIF, LIFR, and S100B) that passed quality control measures were considered for inclusion in the analysis. To increase genetic overlap across NCGAP and IMAGE, genotype data were imputed with the use of the phased data from the HapMap samples (CEU; build 36, release 22) and MACH [http://www.sph.umich.edu/ csg/abecasis/MaCH/download; Li et al., 2009 Li et al., , 2010 . Imputed SNPs with an R 2 value <0.3, indicating poor imputation quality, were excluded from analysis (see Supplementary Table SI for SNP imputation quality). Note that not all SNPs attributed to candidate genes in this build are attributed to the same genes in NCBI build 37.
A total of 2,014 dopaminergic, neurotrophic, angiogenic, kynurenine and cytokine SNPs were available for this study and submitted for quality checks. The majority of these SNPs were not functional. To reduce the number of statistical tests conducted, remaining SNPs with a: (i) minor allele frequency (MAF) <0.1; (ii) genotype frequency below seven; or (iii) in linkage disequilibrium (LD; R 2 ; 0.64) were eliminated. A total of 164 SNPs in dopami nergic, neurotrophic, angiogenic, kynurenine, and cytokine sys tems remained.
Data Analysis
Bivariate correlations and Pearson product-moment correlation coefficients examined the associations among demographic, peri natal risk, and ADHD variables. In addition, t-tests and ANOVAs were used to test for differences between demographic groups on perinatal and ADHD variables. Alpha was set at 0.01 for these analyses.
Generalized Estimating Equations (GEEs) tested for main effects of SNP genotype and birth weight centile range, and the interaction between SNP and birth weight centile range in predicting ADHD symptom severity. Given that within family data are more corre lated than between family data, GEEs account for the family correlation among siblings within the sample. An independent working correlation matrix and the model-based robust estimator covariance matrix were selected, which provides a reliable covari ance estimate even when the correlation matrix is not correctly specified.
Linear GEEs were employed to test the SNP and birth weight centile range main effects on ADHD symptom severity after adjust ing for research site, age, and sex as covariates. Next, to test the hypothesis that SNP genotype moderates the association between birth weight centile and ADHD symptom severity, the covariates of site, age, and sex and main effects of SNP genotype and birth weight centile range were entered into the model, followed by the SNP x birth weight centile range interaction. Wald chi-square tests calcu lated with Type III sums of squares tested the significance of main and interactive effects. In addition, continuous variables were centered to ease the interpretation of model effects. No specific genetic model was assumed in the primary analysis, as the genetic model could differ depending on the genetic variant. Additive, dominant, and recessive genetic models were tested on a secondary basis.
In the GEEs, alpha was set at .01 for nominally significant findings. A total of 164 independent GEEs were calculated. The Benjamini-Hochberg False Discovery Rate (FDR) test [Benjamini and Hochberg, 1995] was used to adjust for multiple comparisons. The FDR q-value threshold was set at 0.05 to determine statistical significance. This study is adequately powered to detect reasonably sized SNP x birth weight centile interactions on ADHD without accounting for multiple testing and is underpowered to detect interactions after FDR correction (Supplementary Table SII) . Exploratory Sobel tests were conducted to examine if birth weight centile mediated the effect of SNPs on ADHD symptom severity. All analyses were completed using SAS.
RESULTS

Demographic, Perinatal, and ADHD Variables
A total of 398 youth participated in the current study (see Table I for sample size by site), including 360 ADHD probands, 21 affected siblings, and 17 unaffected siblings. The sample had a mean age of 10.7 years (SD ¼ 3.02 years; range 5-17 years) and was 83% male. In terms of birth characteristics, the samples' mean birth weight (M ¼ 3,389.25 g; SD ¼ 565 g) and gestational age (M ¼ 39.56 weeks; SD ¼ 1.94 weeks) were in the normal range. Table II gives a summary of the relationships between continu ous demographic, perinatal, and ADHD variables. Older youth had lower birth weight centile range scores and higher CPRS ADHD Total scores. There were no differences between females and males in birth weight centile range (t (396) Analysis of SNP main effects on ADHD symptom severity. After controlling for site, age, sex, and multiple testing, three out of 164 SNPs had a significant main effect on the CPRS Inatten tive score (see Table III and Supplementary Tables SVII and  SVIII for SNP main effects from each statistical model). In the cytokine system, rs10758268 (CNTFR; q ¼ 0.005) and rs7044318 (CNTFR; q ¼ 0.021) genotypes were associated with the CPRS Inattentive score. In the neurotrophic system, rs3825885 (NTRK3; q ¼ 0.021) genotype predicted the CPRS Inattentive score. SNP main effects on ADHD Total Score and Hyperactivi ty-Impulsivity were not significant after adjusting for multiple testing (Table III) .
Main effect of birth weight centile range on ADHD symptom severity. Contrary to the first hypothesis, birth weight centile range was not associated with ADHD Total (b ¼ 0.26; SE ¼ 0.21; 95% CI ¼ -0.15-0.68; P ¼ 0.21), Inattentive (b ¼ 0.28; SE ¼ 0.20; 95% CI ¼ -0.11-0.67; P ¼ 0.16) or Hyperactive-Impulsive (b ¼ 0.14; SE ¼ 0.23; 95% CI ¼ -0.30-0.59; P ¼ 0.53) scores. Note for interpretative purposes the above statistics are from non-transformed ADHD subscale models (P-values are consistent with transformed ADHD subscale models)
Interactions between SNPs and birth weight centile on ADHD symptom severity. Out of the 164 interaction effects tested below without assuming a specific genetic model (Supplementary  Table SIII) , multiple SNP x birth weight centile interactions predicted ADHD symptom severity after multiple testing correc tion (Table IV) . Significant interactions included SNPs within angiogenic, neurotrophic, kynurenine, and cytokine systems. Specifically, for ADHD Total symptom severity, interactions between SNPs within the CCBL1, NTRK1, and NTRK3 genes and birth weight centile range were significant (Fig. 1) . The interaction between a CCBL2 SNP and birth weight centile range predicted Inattentive symptom severity (Fig. 2) . Finally, eleven SNPs in the CCBL1, CCBL2, IL16, NRP1, NRP2, NTRK1, NTRK3, and S100B genes moderated the association between birth weight centile range and Hyperactive-Impulsive symptom severity (Fig. 2) . Interactions involving dopaminergic SNPs were no longer significant after the multiple testing correction.
Exploratory analyses were conducted assuming additive, domi nant, and recessive genetic models. Dominant genetic models produced five interactions predicting ADHD total score, two interactions predicting Inattentive symptom severity, and eleven interactions predicting Hyperactive-Impulsive score after multiple testing correction (Supplementary Table SIV) . Fewer interactions were observed for additive and recessive genetic models (Supple  mentary Tables SV and SVI, respectively) . Finally, sobel tests did not provide evidence that the relationship between individual SNPs and ADHD symptom severity was mediated by birth weight centile for any of the models (results not shown). 
DISCUSSION
Examining biologically informed gene by environment interactions in ADHD may aid in the identification of novel genes associated with ADHD and further the search for neurodevelopmental mech anisms underlying vulnerability for ADHD. Lower birth weight is commonly associated with ADHD [Nigg et al., 2010] ; however, it is unclear what accounts for the phenotypic overlap between restrict ed fetal growth and ADHD. Therefore, this study examined whether SNPs within ischemia-hypoxia responsive systems interact with birth weight centile to predict ADHD symptom severity. Contrary to previous work, lower birth weight centile was not independently associated with increased ADHD symptom sever ity in our data set. In general, literature demonstrates there is an association between restricted fetal growth and ADHD symptom severity [Bhutta et al., 2002; Indredavik et al., 2004; Lahti et al., 2006] , however, null findings have also been reported [Cornforth et al., 2012] . In this sample largely consisting of ADHD cases, levels of inattention and hyperactivity-impulsivity were elevated and represented the upper end of the ADHD risk spectrum. Thus, reduced variability in ADHD symptom severity in case-only [Langley et al., 2007] or family-based designs may have made the relationship between lower birth weight and ADHD more difficult to detect. These results emphasize the heterogeneity in the relationship between lower birth weight and ADHD risk.
Regarding genetic main effects, one SNP within NTRK3 (de scribed below) and two SNPs within CNTFR were associated with ADHD inattentive symptom severity, after adjusting for multiple testing. CNTFR encodes for ciliary neurotrophic factor receptor and is implicated in neurodevelopment and neuron survival [DeChiara et al., 1995] . In independent samples of children and adults, a three-marker CNTFR haplotype was associated with ADHD [Ribases et al., 2008] . Taken together, these findings suggest that CNTFR may be implicated in the development of ADHD.
SNPs within angiogenic, neurotrophic, kynurenine, and cyto kine genes moderated the association between birth weight centile and ADHD symptom severity. In the neurotrophic pathway, NTRK1 and NTRK3 SNPs moderated the association between birth weight centile and ADHD total and hyperactive-impulsive symptom severity. NTRK1 and NTRK3 encode for tyrosine kinase receptors TrkA and TrkC, respectively. Nerve growth factor (NGF) preferentially binds to TrkA whereas neurotrophin-3 (NT3) binds at high affinity to TrkC to promote neuron survival and synaptic plasticity [Lamballe et al., 1991; Reichardt, 2006] , including in hypoxic conditions [Lee et al., 2003; Lin et al., 2006; Ishitsuka et al., 2012] . TrkA is expressed in various neuronal populations including cholinergic neurons in the basal forebrain and striatum [Holtzman et al., 1995] . TrkC is expressed throughout the brain and is most abundant in the hippocampus [Ernfors et al., 1992] . A previous molecular genetic study has implicated neurotrophic factors, especially, NT3, in ADHD risk, though not NTRK1 or NTRK3 [Ribases et al., 2008] . Additionally in the present study, one SNP within NTRK2 moderated the relationship between birth weight centile and ADHD hyperactive-impulsive symptoms at a trend level. Together these findings support the notion that neuro trophic receptor genotype is implicated in the development of ADHD and this relationship may depend on prenatal environmen tal influences, such as ischemia-hypoxia. The angiogenic system regulates the formation of new blood vessels. In the angiogenic system, NRP1 and NRP2 SNPs interacted with birth weight centile to predict hyperactive-impulsive symp tom severity. NRP1 and NRP2 encode for neuropilin-1 and neuro pilin-2, co-receptors for the vascular endothelial growth factor (VEGF) and semaphorin families [Pellet-Many et al., 2008] . NRP1 and NRP2 are expressed in the central nervous system and endothelial cells and play an essential role in vascular develop ment and axonal guidance [Polleux et al., 2000; Rossignol et al., 2000; Gu et al., 2003; Pellet-Many et al., 2008] . Following cerebral ischemia, NRP1 disrupts axonal guidance near the ischemic area [Hou et al., 2008] . Further, NRP1 plays a central role coordinating neuronal migration and guidance of axons that project from the thalamus to the cortex [Lopez-Bendito et al., 2006] , which has been implicated in the development of ADHD [Ivanov et al., 2010; Shaw, 2010] and externalizing behavior problems [Arcos-Burgos et al., 2012] .
Cytokines are implicated in inflammatory, immune, and oxida tive stress responses [Capuron et al., 2011] . Genetic variation in IL16 and S100B interacted with birth weight centile to predict hyperactive-impulsive symptom severity. IL16 encodes for inter leukin-16 and regulates the inflammatory response [Cruikshank et al., 2008] . IL16 is expressed in T-cells, macrophages, and micro glia [Cruikshank et al., 2008; Jana et al., 2009] . S100B, a calcium binding protein, is a glial cytokine with neurotrophic properties [Steiner et al., 2007] . S100B is released in astrocytes following a restricted nutrient and oxygen supply [Gerlach et al., 2006] . Similar to the current findings, IL16 and S100B serum levels are associated with hyperactive-impulsive symptom severity within ADHD cases, and ADHD total symptom severity across cases and controls [Oades et al., 2010] . Within ADHD cases, S100B and IL16 serum levels have also been linked to pre-and perinatal risk factors including birth weight, gestational age, and maternal smoking during pregnancy [Oades, 2011] , which makes them good candidates for a role in disease etiology.
The kynurenine pathway metabolizes tryptophan and plays a role in glial and dopaminergic functioning, as well as inflammatory and immune responses [Steiner et al., 2012; Vecsei et al., 2013] . SNPs within CCBL1 and CCBL2 moderated the relationship be tween ADHD total, inattentive, and hyperactive-impulsive symp tom severity. CCBL1 and CCBL2 encode kynurenine aminotrans ferase I and II, respectively, which transaminate kynurenine into the neuroprotective kynurenic acid [Guillemin et al., 2007; Myint et al., 2007; Vecsei et al., 2013] . Kynurenic acid is an antagonist at the N-mehtyl D-aspartic acid (NMDA) and a7 nicotinic acety lochoine (a7nACH) receptors that are implicated in learning [Hilmas et al., 2001] . In rats, kynurenic acid in the prefrontal cortex is inversely related to glutamate, acetylcholine and dopamine levels, a relationship that has been detected even with minor changes in kynurenic acid [Wonodi et al., 2010] . In youth with ADHD, kynurenic acid in serum was positively associated with adverse events during the third trimester, at a trend level [Oades, 2011] . In light of these findings, prenatal ischemia-hypoxia may put individuals with susceptible CCBL1 and CCBL2 genotypes at risk for ADHD by leading to suboptimal expression of kynur enine aminotransferase I and II. Thus, variability in cytokine and kynurenine genes may alter risk for ADHD following exposure to pre-and perinatal risk, potentially by affecting glial functioning [Todd and Botteron, 2001; Russell et al., 2006; Oades et al., 2010] .
We are encouraged by the promising findings of this study, but also recognize there are some study limitations. First, this study had a modest sample size and therefore, replication studies of these results are warranted. Second, youth in the study were either diagnosed with ADHD or at genetic risk for ADHD by nature of having a sibling with ADHD. This resulted in constrained variabil ity in ADHD symptom severity compared with the general popu lation which could have reduced statistical power and the likelihood of significant findings. Third, birth weight centile range served as a proxy measure for an adverse intrauterine environment as no direct measure was available. Therefore, inferences about the underlying environmental pathogen were made in this study. Fourth, this design is unable to methodological control for genetic determinants of birth weight. This allows for the possibility that that genetic, rather than environmental determinants of birth weight are inter acting with SNPs to predict the ADHD phenotype. Fifth, we also acknowledge that we used an earlier NCBI build of the genome and as a result, some of the SNPs that we analyzed are now attributed to other genes. For example, SNPs identified in significant interactions which are no longer attributed to the same gene include: rs962879 (NTRK1 to CD1B), rs10793967 (CCBL1 to ABL1), rs4656076 (CCBL2 to GBP3), rs10922552 (CCBL2 to intergenic region) and rs13419677 (NRP2 to PARD3B). Thus, it is possible that the association signals we detected are in LD with a genetic variant in a neighboring gene. Finally, the design of this study was unable to rule-out the effect of maternal genotype on the observed SNP x birth weight centile range interactions [Waldman, 2007] . Future research should include both maternal and child genotype when investigat ing the developmental origins of ADHD.
Taken together, this study raises the possibility that angiogenic, neurotrophic, cytokine and kynurenine genetic variants moderate the association between birth weight and ADHD symptom severity. To our knowledge, this is the first study to support the involvement of CCBL1, CCBL2, IL16, NRP1, NRP2, NTRK1, NTRK3, and S100B genes in the development of ADHD which highlights the impor tance of including measures of environmental risk when searching for novel genetic variants associated with ADHD. Although overall the pattern of results is consistent with expectations, we are pursuing replication datasets to further elucidate the relationships between these SNPs, birth weight centile, and ADHD risk. If replicated, these results provide a basis for future targeted gene methylation investigations. Findings also support the use of the DOHaD framework [Gluckman et al., 2004] in conceptualizing the etiological underpinnings of the association between lower birth weight and ADHD. Further application of this framework may aid in isolating specific prenatal environmental pathogens and genetic/ epigenetic pathways implicated in the development of ADHD. 
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